ECHOCARDIOGRAPHIC PROFILE IN THE PATIENTS OF CHRONIC KIDNEY DISEASE

Main Article Content

Dr. Anuj Bagga
Dr. Kumar Jee Kaul

Keywords

Chronic kidney disease, Glomerular filtration rate (GFR), Cockcroft-Gault equation, Echocardiographic profile, Cardiac dysfunction, Albumin excretion, Serum creatinine, Creatinine clearance, LV mass, IVSd (interventricular septal thickness in diastole), LVPWDd (left ventricular posterior wall thickness in diastole), LVIDd (left ventricular internal diameter in diastole), CKD stages, Echocardiography, LV function, LV dysfunction, Cardio renal syndrome

Abstract

Background:- Chronic kidney disease can be defined as the presence of kidney damage, manifested by abnormal albumin excretion or decreased kidney function, quantified by measured or estimated glomerular filtration rate (GFR), that persists for more than three months. Although creatinine clearances can be calculated from the serum creatinine concentration by using either the Cockcroft-Gault equation. The need of this study, giving analysis of cardiac dysfunction and early management of patients suffering from chronic kidney disease.


METHODS:- we analysed a total of 122 patients and divide them into different staged of CKD according to their calculated eGFR by Cockcroft-Gault equation and kept 20 patients is in control group, which were evaluated from cardiac function by mean of echocardiography. Other parameters like weight, age, serum creatinine were used to calculate eGFR and IVSd, LVPWDd, LVIDd were used to calculate LV mass.


RESULTS:- Among patients of CKD 20.5% were females and 79.5% were males. The mean age group was 52.09 years. 8.2% patients were in CKD stage 1, 9.8% patients were in CKD stage II and stage III, 24.6% patients were in stage IV and 47.5% patients were in stage V. The mean creatinine clearance was 28.48. 30.3% patients with normal LV function, 22.1% with mild LV dysfunction, 24.6% patients with moderate LV dysfunction and 23.0% patients with severe LV dysfunction. The mean LV function was 43.39. In concern with LV mass 27.0% patients have severely abnormal LV mass, 23.0% have moderately abnormal LV mass, 19.7% have mildly abnormal LVmass and 30.3% patients with normal LV mass. The mean LV mass was 249.78 gms.


CONCLUSION: - In this study, we conclude that, patients having chronic kidney disease had significant cardiac dysfunction. Hence, LV mass increases with increase in stage of chronic kidney disease and LV dysfunction also increases with increase in staging of chronic kidney disease.

Abstract 119 | pdf Downloads 64

References

1. Thomas R, Kanso A, Sedor JR. Chronic kidney disease and its complications. Primary care: Clinics in office practice. 2008 Jun 1;35 (2):329-44.
2. Coresh J, Selvin E, Stevens LA, Manzi J, Kusek JW, Eggers P, Van Lente F, Levey AS. Prevalence of chronic kidney disease in the United States. Jama. 2007 Nov 7;298 (17):2038-47.
3. Singh AK, Farag YM, Mittal BV, Subramanian KK, Reddy SR, Acharya VN, Almeida AF, Channakeshavamurthy A, Ballal HS, Gaccione P, Issacs R. Epidemiology and risk factors of chronic kidney disease in India–results from the SEEK (Screening and Early Evaluation of Kidney Disease) study. BMC nephrology. 2013 Dec;14 (1):114.
4. Saunders WB. KDOQI clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease. 2007;16(3):445-8
5. Levey AS, Eckardt KU, Tsukamoto Y, Levin A, Coresh J, Rossert J, Zeeuw DD, Hostetter TH, Lameire N, Eknoyan G. Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney international. 2005 Jun 1;67 (6):2089-100.
6. Coresh J, Astor BC, Greene T, Eknoyan G, Levey AS. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. American journal of kidney diseases. 2003 Jan 1;41(1):1-2.
7. Herzog CA, Ma JZ, Collins AJ. Poor long-term survival after acute myocardial infarction among patients on long-term dialysis. New England Journal of Medicine. 1998 Sep 17;339(12):799-805.
8. Weiner DE, Tighiouart H, Stark PC, Amin MG, MacLeod B, Griffith JL, Salem DN, Levey AS, Sarnak MJ. Kidney disease as a risk factor for recurrent cardiovascular disease and mortality1. American Journal of Kidney Diseases. 2004 Aug 1;44(2):198-206
9. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. American Journal of Kidney Diseases. 1998 Nov 1;32(5):S112-9.
10. Schunkert H, Hense HW. A heart price to pay for anaemia. Nephrology Dialysis Transplantation. 2001 Mar 1;16(3):445-8.
11. Rostand SG, Kirk KA, Rutsky EA. Dialysis-associated ischemic heart disease: insights from coronary angiography. Kidney international. 1984 Apr 1;25(4):653-9.
12. Schwarz U, Buzello M, Ritz E, Stein G, Raabe G, Wiest G, Mall G, Amann K. Morphology of coronary atherosclerotic lesions in patients with end-stage renal failure. Nephrology Dialysis Transplantation. 2000 Feb 1;15(2):218-23.
13. Wang MC, Tsai WC, Chen JY, Huang JJ. Stepwise increase in arterial stiffness corresponding with the stages of chronic kidney disease. American Journal of Kidney Diseases. 2005 Mar 1;45(3):494-501.
14. Klassen PS, Lowrie EG, Reddan DN, DeLong ER, Coladonato JA, Szczech LA, Lazarus JM, Owen Jr WF. Association between pulse pressure and mortality in patients undergoing maintenance hemodialysis. Jama. 2002 Mar 27;287(12):1548-55.
15. Goolsby MJ. National Kidney Foundation Guidelines for chronic kidney disease: evaluation, classification, and stratification. Journal of the American Academy of Nurse Practitioners. 2002 Jun;14(6):238-42.
16. Levin A, Foley RN. Cardiovascular disease in chronic renal insufficiency. American journal of kidney diseases. 2000 Dec 1;36(6):S24-30.
17. McClellan W, Aronoff SL, Bolton WK, Hood S, Lorber DL, Tang KL, Tse TF, Wasserman B, Leiserowitz M. The prevalence of anemia in patients with chronic kidney disease. Current medical research and opinion. 2004 Sep 1;20(9):1501-10.
18. McClellan W, Aronoff SL, Bolton WK, Hood S, Lorber DL, Tang KL, Tse TF, Wasserman B, Leiserowitz M. The prevalence of anemia in patients with chronic kidney disease. Current medical research and opinion. 2004 Sep 1;20(9):1501-10.
19. Moe S, Drüeke T, Cunningham J, Goodman W, Martin K, Olgaard K, Ott S, Sprague S, Lameire N, Eknoyan G. Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney international. 2006 Jun 1;69(11):1945-53.
20. Gal-Moscovici A, Sprague SM. Bone health in chronic kidney disease– mineral and bone disease. Advances in chronic kidney disease. 2007 Jan 1;14(1):27-36.
21. Foley RN, Parfrey PS, Sarnak MJ. Epidemiology of cardiovascular disease in chronic renal disease. Journal of the American Society of Nephrology: JASN. 1998 Dec;9(12 Suppl):S16-23.
22. Muntner P, He J, Astor BC, Folsom AR, Coresh J. Traditional and nontraditional risk factors predict coronary heart disease in chronic kidney disease: results from the atherosclerosis risk in communities study. Journal of the American Society of Nephrology. 2005 Feb 1;16(2):529-38.
23. Tonelli M, Keech A, Shepherd J, Sacks F, Tonkin A, Packard C, Pfeffer M, Simes J, Isles C, Furberg C, West M. Effect of pravastatin in people with diabetes and chronic kidney disease. Journal of the American Society of Nephrology. 2005 Dec 1;16(12):3748-54.
24. Levin A, Singer J, Thompson CR, Ross H, Lewis M. Prevalent left ventricular hypertrophy in the predialysis population: identifying opportunities for intervention. American Journal of Kidney Diseases. 1996 Mar 1;27(3):347-54.
25. Bibbins-Domingo K, Chertow GM, Fried LF, Odden MC, Newman AB, Kritchevsky SB, Harris TB, Satterfield S, Cummings SR, Shlipak MG. Renal function and heart failure risk in older black and white individuals: the Health, Aging, and Body Composition Study. Archives of internal medicine. 2006 Jul 10;166(13):1396-402.
26. Kasiske BL. Hyperlipidemia in patients with chronic renal disease. American journal of kidney diseases. 1998 Nov 1;32(5):S142-56.
27. Shulman NB, Ford CE, Hall WD, Blaufox MD, Simon D, Langford HG, Schneider KA. Prognostic value of serum creatinine and effect of treatment of hypertension on renal function. Results from the hypertension detection and follow-up program. The Hypertension Detection and Follow-up Program Cooperative Group. Hypertension. 1989 May 1;13(5 Suppl):I80.
28. Locatelli F, Pozzoni P, Tentori F, Del Vecchio L. Epidemiology of cardiovascular risk in patients with chronic kidney disease. Nephrology Dialysis Transplantation. 2003 Aug 1;18(suppl_7):vii2-9.
29. London GM, Parfrey PS. Cardiac disease in chronic uremia: pathogenesis. Advances in renal replacement therapy. 1997 Jul 1;4(3):194-211.
30. Wright J, Hutchison A. Cardiovascular disease in patients with chronic kidney disease. Vascular health and risk management. 2009;5:713.
31. Foley RN, Parfrey PS, Harnett JD, Kent GM, Martin CJ, Murray DC, Barre PE. Clinical and echocardiographic disease in patients starting end-stage renal disease therapy. Kidney international. 1995 Jan 1;47(1):186-92.
32. Mark PB, Johnston N, Groenning BA, Foster JE, Blyth KG, Martin TN, Steedman T, Dargie HJ, Jardine AG. Redefinition of uremic cardiomyopathy by contrast-enhanced cardiac magnetic resonance imaging. Kidney international. 2006 May 2;69(10):1839-45.
33. Cannella G, La Canna G, Sandrini M, Gaggiotti M, Nordio G, Movilli E, Mombelloni S, Visioli O, Maiorca R. Reversal of left ventricular hypertrophy following recombinant human erythropoietin treatment of anaemic dialysed uraemic patients. Nephrology Dialysis Transplantation. 1991 Jan 1;6(1):31-7.
34. Pascual J, Teruel JL, Moya JL, Liano F, Jimenez-Mena M, Ortuno J. Regression of left ventricular hypertrophy after partial correction of anemia with erythropoietin in patients on hemodialysis: a prospective study. Clinical nephrology. 1991 Jun;35(6):280-7.
35. Pennell DJ, Sechtem UP, Higgins CB, Manning WJ, Pohost GM, Rademakers FE, van Rossum AC, Shaw LJ, Kent Yucel E. Clinical indications for cardiovascular magnetic resonance (CMR): Consensus Panel report. Journal of Cardiovascular Magnetic Resonance. 2004 Jan 1;6(4):727-65.
36. Flett AS, Westwood MA, Davies LC, Mathur A, Moon JC. The prognostic implications of cardiovascular magnetic resonance. Circulation: Cardiovascular Imaging. 2009 May 1;2(3):243-50.
37. Perazella MA. Current status of gadolinium toxicity in patients with kidney disease. Clinical Journal of the American Society of Nephrology. 2009 Feb 1;4(2):461-9.
38. Bennett CL, Qureshi ZP, Sartor AO, Norris LB, Murday A, Xirasagar S, Thomsen HS. Gadolinium-induced nephrogenic systemic fibrosis: the rise and fall of an iatrogenic disease. Clinical kidney journal. 2012 Feb 1;5(1):82-8.
39. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, Picard MH, Roman MJ, Seward J, Shanewise JS, Solomon SD. Recommendations for chamber quantification: a report from the American Society of Echocardiography’s Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. Journal of the American Society of Echocardiography. 2005 Dec 1;18(12):1440-63.
40. Nagueh SF, Appleton CP, Gillebert TC, Marino PN, Oh JK, Smiseth OA, Waggoner AD, Flachskampf FA, Pellikka PA, Evangelisa A. Recommendations for the evaluation of left ventricular diastolic function by echocardiography. European Journal of Echocardiography. 2009 Mar 1;10(2):165-93.
41. Park M, Hsu CY, Li Y, Mishra RK, Keane M, Rosas SE, Dries D, Xie D, Chen J, He J, Anderson A. Associations between kidney function and subclinical cardiac abnormalities in CKD. Journal of the American Society of Nephrology. 2012 Oct 1;23(10):1725-34.
42. Cai QZ, Lu XZ, Lu Y, Wang AY. Longitudinal changes of cardiac structure and function in CKD (CASCADE study). Journal of the American Society of Nephrology. 2014 Feb 13:ASN-2013080899.
43. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. American Journal of Kidney Diseases. 1998 Nov 1;32(5):S112-9.
44. London GM, Pannier B, Guerin AP, Blacher J, Marchais SJ, Darne B, Metivier F, Adda H, Safar ME. Alterations of left ventricular hypertrophy in and survival of patients receiving hemodialysis: follow- up of an interventional study. Journal of the American Society of Nephrology. 2001 Dec 1;12(12):2759-67.
45. Liu YW, Su CT, Sung JM, Wang SP, Su YR, Yang CS, Tsai LM, Chen JH, Tsai WC. Association of left ventricular longitudinal strain with mortality among stable hemodialysis patients with preserved left ventricular ejection fraction. Clinical Journal of the American Society of Nephrology. 2013 Sep 6;8(9):1564-74.
46. Pecoits-Filho R, Barberato SH. Echocardiography in chronic kidney disease: diagnostic and prognostic implications. Nephron Clinical practice. 2010;114(4):c242-7.
47. Eckardt KU, Scherhag A, Macdougall IC, Tsakiris D, Clyne N, Locatelli F, Zaug MF, Burger HU, Drueke TB. Left ventricular geometry predicts cardiovascular outcomes associated with anemia correction in CKD. Journal of the American Society of Nephrology. 2009 Oct 22:ASN- 2009060631.
48. Silaruks S, Sirivongs D, Chunlertrith D. Left ventricular hypertrophy and clinical outcome in CAPD patients. Peritoneal dialysis international. 2000 Jan 1;20(4):461-6.
49. Chen SC, Chang JM, Liu WC, Tsai YC, Tsai JC, Su HM, Hwang SJ, Chen HC. Stepwise increases in left ventricular mass index and decreases in left ventricular ejection fraction correspond with the stages of chronic kidney disease in diabetes patients. Experimental diabetes research. 2011 Aug 11;2012.
50. Levin A, Singer J, Thompson CR, Ross H, Lewis M. Prevalent left ventricular hypertrophy in the predialysis population: identifying opportunities for intervention. American Journal of Kidney Diseases. 1996 Mar 1;27(3):347-54.
51. Levin A, Thompson CR, Ethier J, Carlisle EJ, Tobe S, Mendelssohn D, Burgess E, Jindal K, Barrett B, Singer J, Djurdjev O. Left ventricular mass index increase in early renal disease: impact of decline in hemoglobin. American Journal of Kidney Diseases. 1999 Jul 1;34(1):125-34.
52. Paoletti E, Bellino D, Cassottana P, Rolla D, Cannella G. Left ventricular hypertrophy in nondiabetic predialysis CKD. American journal of kidney diseases. 2005 Aug 1;46(2):320-7.
53. Stewart GA, Gansevoort RO, Mark PB, Rooney E, Mcdonagh TA, Dargie HJ, Stuart R, Rodger C, Jardine AG. Electrocardiographic abnormalities and uremic cardiomyopathy. Kidney international. 2005 Jan 1;67(1):217-26.
54. Zoccali C. How important is echocardiography for risk stratification in follow-up of patients with chronic kidney disease?. Nature Reviews Nephrology. 2007 Apr 1;3(4):178.
55. Harnett JD, Parfrey PS, Griffiths SM, Gault MH, Barre P, Guttmann RD. Left ventricular hypertrophy in end-stage renal disease. Nephron. 1988;48(2):107-15.
56. Olivero JJ, Nguyen PT. Chronic kidney disease: a marker of cardiovascular disease. Methodist DeBakey cardiovascular journal. 2009;5(2):24-9.
57. Rodriguez-Iturbe B, Correa-Rotter R. Cardiovascular risk factors and prevention of cardiovascular disease in patients with chronic renal disease. Expert opinion on pharmacotherapy. 2010 Nov 1;11(16):2687- 98.
58. Zoccali C, Benedetto FA, Tripepi G, Mallamaci F, Rapisarda F, Seminara G, Bonanno G, Malatino LS. Left ventricular systolic function monitoring in asymptomatic dialysis patients: a prospective cohort study. Journal of the American Society of Nephrology. 2006 May 1;17(5):1460-5.
59. Silberberg JS, Barre PE, Prichard SS, Sniderman AD. Impact of left ventricular hypertrophy on survival in end-stage renal disease. Kidney international. 1989 Aug 1;36(2):286-90.
60. Cintron G, Johnson G, Francis G, Cobb F, Cohn JN. Prognostic significance of serial changes in left ventricular ejection fraction in patients with congestive heart failure. The V-HeFT VA Cooperative Studies Group. Circulation. 1993 Jun;87(6 Suppl):VI17-23.
61. Kürşat S, Tekçe H, Ekmekçi C, Çolak HB, Alıcı T. Relationship between the degree of malnutrition and echocardiographic parameters in hemodialysis patients. Nephron Clinical Practice. 2007;106(3):c136-42.
62. Hillege HL, Girbes AR, de Kam PJ, Boomsma F, de Zeeuw D, Charlesworth A, Hampton JR, van Veldhuisen DJ. Renal function, neurohormonal activation, and survival in patients with chronic heart failure. Circulation. 2000 Jul 11;102(2):203-10.
63. Levin NW, Handelman GJ, Coresh J, Port FK, Kaysen GA. Reverse epidemiology: a confusing, confounding, and inaccurate term. InSeminars in dialysis 2007 Nov (Vol. 20, No. 6, pp. 586-592). Oxford, UK: Blackwell Publishing Ltd.
64. Io H, Matsumoto M, Okumura K, Sato M, Masuda A, Furukawa M, Nohara N, Tanimoto M, Kodama F, Hagiwara S, Gohda T. Predictive factors associated with left ventricular hypertrophy at baseline and in the follow‐up period in non‐diabetic hemodialysis patients. InSeminars in dialysis 2011 May (Vol. 24, No. 3, pp. 349-354). Oxford, UK: Blackwell Publishing Ltd.
65. Trovato GM, Iannetti E, Catalano D, Squatrito R, Vitale M, Zuccala G. Heart failure and nutritional status in hemodialysis. Recenti progressi in medicina. 2001 Nov;92(11):655-9.
66. Wing AJ, Brunner FP, Brynger H, Jacobs C, Kramer P, Selwood NH, Gretz N. Cardiovascular-related causes of death and the fate of patients with renovascular disease. In Cardiocirculatory Function in Renal Disease 1984 (Vol. 41, pp. 306-311). Karger Publishers.
67. Silberberg JS, Barre PE, Prichard SS, Sniderman AD. Impact of left ventricular hypertrophy on survival in end-stage renal disease. Kidney international. 1989 Aug 1;36(2):286-90.
68. Laddha M, Sachdeva V, Diggikar PM, Satpathy PK, Kakrani AL. Echocardiographic assessment of cardiac dysfunction in patients of end stage renal disease on haemodialysis. Journal of Association of Physicians of India. 2014 Jan;62:28-33.
69. Zoccali C, Tripepi G, Dounousi E, Mallamaci F. Chronic kidney disease (CKD) as a systemic disease: whole body autoregulation and inter-organ cross-talk. Kidney and Blood Pressure Research. 2014;39(2-3):134-41.
70. Sato W, Kosaka T, Koyama T, Ishida M, Iino K, Watanabe H, Ito H. Impaired renal function is a major determinant of left ventricular diastolic dysfunction: assessment by stress myocardial perfusion imaging. Annals of nuclear medicine. 2013 Oct 1;27(8):729-36.
71. Masugata H, Senda S, Goda F, Yamagami A, Okuyama H, Kohno T, Hosomi N, Yukiiri K, Noma T, Imai M, Kiyomoto H. Echocardiographic assessment of the cardio-renal connection: is left ventricular hypertrophy or diastolic function more closely correlated with estimated glomerular filtration rate in patients with cardiovascular risk factors?. Clinical and experimental hypertension. 2010 Apr 1;32(2):113-20.
72. Segall L, Nistor I, Covic A. Heart failure in patients with chronic kidney disease: a systematic integrative review. BioMed research international. 2014;2014.
73. Sood MM, Pauly RP, Rigatto C, Komenda P. Left ventricular dysfunction in the haemodialysis population.
74. Singal KK, Singal N, Gupta P, Chander J, Relan P. Cardiac status in patients of chronic kidney disease: an assessment by non-invasive tools. Bangladesh Journal of Medical Science. 2016 Apr 1;15(2):207-15.
75. Bullock RE, Amer HA, Simpson I, Ward MK, Hall RJ. Cardiac abnormalities and exercise tolerance in patients receiving renal replacement therapy. Br Med J (Clin Res Ed). 1984 Dec 1;289(6457):1479-84.
76. Franczyk-Skóra B, Gluba A, Olszewski R, Banach M, Rysz J. Heart function disturbances in chronic kidney disease–echocardiographic indices. Archives of medical science: AMS. 2014 Dec 22;10(6):1109.
77. Singal KK, Singal N, Gupta P, Chander J, Relan P. Cardiac status in patients of chronic kidney disease: an assessment by non-invasive tools. Bangladesh Journal of Medical Science. 2016 Apr 1;15(2):207-15.
78. Debnath A, Chaudhury SR, Chaturvedi AN. Echocardiographic assessment of left ventricular systolic dysfunction in chronic kidney disease patients of a rural tertiary medical care centre in West Bengal. IOSR-JDMS. 2014;13(1):69-73.
79. Hayashi SY, Rohani M, Lindholm B, Brodin LÅ, Lind B, Barany P, Alvestrand A, Seeberger A. Left ventricular function in patients with chronic kidney disease evaluated by colour tissue Doppler velocity imaging. Nephrology Dialysis Transplantation. 2005 Oct 11;21(1):125- 32.
80. Oh JK, Seward JB, Tajik AJ, editors. The echo manual. Lippincott Williams & Wilkins; 2006 Jan; (7):141-48.
81. FONAROW, Gregg C.; HSU, Jeffrey J. Left ventricular ejection fraction: what is “normal”?. 2016 Dec;14(1):114.
82. Rajapurkar MM, John GT, Kirpalani AL, Abraham G, Agarwal SK, Almeida AF, Gang S, Gupta A, Modi G, Pahari D, Pisharody R. What do we know about chronic kidney disease in India: first report of the Indian CKD registry. BMC nephrology. 2012 Dec;13(1):10.
83. Singh AK, Farag YM, Mittal BV, Subramanian KK, Reddy SR, Acharya VN, Almeida AF, Channakeshavamurthy A, Ballal HS, Gaccione P, Issacs R. Epidemiology and risk factors of chronic kidney disease in India–results from the SEEK (Screening and Early Evaluation of Kidney Disease) study. BMC nephrology. 2013 Dec;14(1):114
84. Zhang L, Wang F, Wang L, Wang W, Liu B, Liu J, Chen M, He Q, Liao Y, Yu X, Chen N. Prevalence of chronic kidney disease in China: a cross- sectional survey. The Lancet. 2012 Mar 3;379(9818):815-22.
85. Debbarma DR, Gope DM. Echocardiographic profile in patients under maintenance haemodialysis. Age (year).;53:10-5.
86. Nasri H. World Kidney Day 2014; Chronic Kidney Disease and Aging: A Global Health Alert. Iranian journal of public health. 2014;43(1):126-7.
87. Centers for Disease Control and Prevention. National chronic kidney disease fact sheet: general information and national estimates on chronic kidney disease in the United States, 2010. Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control and Prevention. 2010.
88. Chen SC, Chang JM, Liu WC, Tsai YC, Tsai JC, Su HM, Hwang SJ, Chen HC. Stepwise increases in left ventricular mass index and decreases in left ventricular ejection fraction correspond with the stages of chronic kidney disease in diabetes patients. Experimental diabetes research. 2011 Aug 11;2012.
89. Chan KL. Feigenbaum’s Echocardiography, 6th edn. Harvey Feigenbaum, William F Armstrong and Thomas Ryan (2004). The Canadian journal of cardiology. 2007 Feb;23(2):100.
90. Foppa M, Duncan BB, Rohde LE. Echocardiography-based left ventricular mass estimation. How should we define hypertrophy?. Cardiovascular ultrasound. 2005 Dec;3(1):17.
91. Troy BL, Pombo J, Rackley CE. Measurement of left ventricular wall thickness and mass by echocardiography. Circulation. 1972 Mar 1;45(3):602-11.